A detailed history of National Bank Of Canada transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, National Bank Of Canada holds 400 shares of TVTX stock, worth $5,596. This represents 0.0% of its overall portfolio holdings.

Number of Shares
400
Previous 400 -0.0%
Holding current value
$5,596
Previous $3,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 10, 2023

BUY
$7.64 - $17.25 $3,056 - $6,900
400 New
400 $3,000
Q4 2022

Jan 24, 2023

BUY
$18.47 - $26.14 $1.24 Million - $1.75 Million
67,000 Added 136.73%
116,000 $0
Q3 2022

Oct 13, 2022

BUY
$22.91 - $28.63 $1.12 Million - $1.4 Million
49,000 New
49,000 $1.21 Million

Others Institutions Holding TVTX

About Travere Therapeutics, Inc.


  • Ticker TVTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,173,600
  • Market Cap $898M
  • Description
  • Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...
More about TVTX
Track This Portfolio

Track National Bank Of Canada Portfolio

Follow National Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of National Bank Of Canada , based on Form 13F filings with the SEC.

News

Stay updated on National Bank Of Canada with notifications on news.